W
William F. Keane
Researcher at University of Minnesota
Publications - 243
Citations - 37609
William F. Keane is an academic researcher from University of Minnesota. The author has contributed to research in topics: Renal function & Kidney disease. The author has an hindex of 75, co-authored 242 publications receiving 36725 citations. Previous affiliations of William F. Keane include Tufts University & University of Copenhagen.
Papers
More filters
Journal Article
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
Andrew S. Levey,Josef Coresh,Kline Bolton,Bruce Culleton,Kathy Schiro Harvey,T. Alp Ikizler,Cynda Ann Johnson,Annamaria T. Kausz,Paul L. Kimmel,John W. Kusek,Adeera Levin,Kenneth L. Minaker,Robert Nelson,Helmut G. Rennke,Michael Steffes,Beth Witten,Ronald J. Hogg,Susan Furth,Kevin V. Lemley,Ronald J. Portman,George Schwartz,Joseph Lau,Ethan M Balk,Ronald D. Perrone,Tauqeer Karim,Lara Rayan,Inas Al-Massry,Priscilla Chew,Brad C. Astor,Deirdre De Vine,Garabed Eknoyan,Nathan W. Levin,Sally Burrows-Hudson,William F. Keane,Alan S. Kliger,Derrick Latos,Donna Mapes,Edith Oberley,Kerry Willis,George R. Bailie,Gavin J. Becker,Jerrilynn Burrowes,David Churchill,Allan J. Collins,William Couser,Dick DeZeeuw,Alan Garber,Thomas Golper,Frank A. Gotch,Antonio M. Gotto,Joel W. Greer,Richard H. Grimm,Ramon G. Hannah,Jaime Herrera Acosta,Ronald J. Hogg,Lawrence G. Hunsicker,Michael J. Klag,Saulo Klahr,Caya Lewis,Edmund G. Lowrie,Arthur J. Matas,Sally McCulloch,Maureen Michael,Joseph V. Nally,John M. Newmann,Allen R. Nissenson,Keith Norris,William F. Owen,Thakor G. Patel,Glenda Payne,Rosa A. Rivera-Mizzoni,David A. Smith,Robert A. Star,Theodore Steinman,Fernando Valderrábano,John Walls,Jean Pierre Wauters,Nanette Wenger,Josephine P. Briggs +78 more
TL;DR: In the early 1990s, the National Kidney Foundation (K/DOQI) developed a set of clinical practice guidelines to define chronic kidney disease and to classify stages in the progression of kidney disease.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Nephropathy in diabetes
Mark E. Molitch,Ralph A. DeFronzo,Marion J. Franz,William F. Keane,Carl Erik Mogensen,Hans-Henrik Parving,Michael W. Steffes +6 more
Journal ArticleDOI
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
Dick de Zeeuw,Giuseppe Remuzzi,Hans-Henrik Parving,William F. Keane,Zhongxin Zhang,Shahnaz Shahinfar,Steve Snapinn,Mark E. Cooper,William E. Mitch,Barry M. Brenner +9 more
TL;DR: Albuminuria is the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk and the stronger the renal protection.
Journal ArticleDOI
Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy
Dick de Zeeuw,Giuseppe Remuzzi,Hans-Henrik Parving,William F. Keane,Zhongxin Zhang,Shahnaz Shahinfar,Steve Snapinn,Mark E. Cooper,William E. Mitch,Barry M. Brenner +9 more
TL;DR: Albuminuria is an important factor predicting cardiovascular risk in patients with type 2 diabetic nephropathy, and reducing albuminuria in the first 6 months appears to afford cardiovascular protection in these patients.